Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Bone Marrow Stem Cells in ALS
NCT02286011Phase 1Unknown
- Sponsor
- Red de Terapia Celular
- Start
- Nov 2014
- Primary completion
- Dec 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of autologous bone marrow-derived mononuclear cell in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Red de Terapia Celular. Primary endpoint: Rate of serious and non-serious adverse events related to the use of bone marrow mononuclear cells at 24 months. Status: unknown.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02286011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02286011.